Assuntos
Neoplasias/terapia , Dor Intratável/terapia , Adulto , Analgésicos não Narcóticos/classificação , Analgésicos não Narcóticos/uso terapêutico , Analgésicos Opioides/classificação , Analgésicos Opioides/uso terapêutico , Criança , Relação Dose-Resposta a Droga , Esquema de Medicação , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Neoplasias/fisiopatologia , Medição da Dor , Dor Intratável/fisiopatologia , Dor Intratável/psicologia , Cuidados Paliativos , Qualidade da Assistência à Saúde , Qualidade de VidaRESUMO
Anthracyclines containing regimen are widely used in advanced breast cancer. The response to first line chemotherapy varies according to many individual factors and the theoretical response to a given protocol cannot predict the response of a patient. A randomized clinical trial (ERASME) was initiated in order to evaluate the more appropriate first line chemotherapy scheme in advanced breast cancer. Prognostic factors were included in a multiple logistic regression to explain the response after the first 3 chemotherapy courses (monthly FEC). Three factors were found to be statistically significant: adjuvant hormonotherapy, loco-regional metastases, adjuvant adriamycin containing regimen (pejorative prognostic factor). By combining these factors, this statistical model enables us to predict a response rate to a first line chemotherapy from 27 to 87%. Such a model can be taken into account in a decision-making procedure of first line chemotherapy in advanced breast cancer.